AMAG Pharmaceuticals Deuda/Patrimonio neto
¿Qué es el Deuda/Patrimonio neto de AMAG Pharmaceuticals?
El Deuda/Patrimonio neto de AMAG Pharmaceuticals, Inc. es N/A
¿Cuál es la definición de Deuda/Patrimonio neto?
La relación deuda / patrimonio neto es una relación financiera que indica la proporción relativa del capital contable y la deuda utilizada para financiar los activos de una empresa.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
¿Qué hace AMAG Pharmaceuticals?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.